Singapore markets closed

Straits Times Index
3,258.90
+1.72(+0.05%)
Nikkei
28,041.48
+258.55(+0.93%)
Hang Seng
20,400.11
+90.98(+0.45%)
FTSE 100
7,631.74
+11.31(+0.15%)
Bitcoin USD
28,430.59
+168.57(+0.60%)
CMC Crypto 200
621.79
+7.58(+1.23%)

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

1.9300

-0.0900

(-4.46%)

At close: 04:00PM EDT

1.9400

+0.01

(+0.52%)

After hours:

05:19PM EDT

Trade prices are not sourced from all markets

All

Reuters
French biotech Cellectis takes stake in Mayflower-backed startup Primera
Cellectis, which gets a seat on Primera's board, will collaborate with Primera on the development of therapies for mitochondrial diseases, a group of genetic disorders. Under terms of the deal, if Primera chooses to exclusively license up to five co-developed therapies from Cellectis, it will be eligible to get up to $750 million in milestone payments.
Zacks
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Zacks
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.